arhalofenate and tofisopam

Over the past decade much has been learned about the mechanisms of crystal-induced inflammation and renal excretion of uric acid, which has led to more specific targeting of gout therapies and a more potent approach to future management of gout. This article outlines agents being developed for more aggressive lowering of urate and more specific anti-inflammatory activity. The emerging urate-lowering therapies include lesinurad, arhalofenate, ulodesine, and levotofisopam. Novel gout-specific anti-inflammatories include the interleukin-1β inhibitors anakinra, canakinumab, and rilonacept, the melanocortins, and caspase inhibitors. The historic shortcomings of current gout treatment may, in part, be overcome by these novel approaches.

Topics: Acetamides; Adrenocorticotropic Hormone; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Benzodiazepines; Febuxostat; Gout; Gout Suppressants; Humans; Imino Furanoses; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Melanocortins; Phenylacetates; Polyethylene Glycols; Pyrimidinones; Recombinant Fusion Proteins; Thiazoles; Thioglycolates; Triazoles; Urate Oxidase; Uricosuric Agents